Erin Bowles, MPH

Bowles_Erin_J_205x293.jpg

“At KPWHRI, we have access to extensive data on cancer care. I'm using the data to learn how to improve the experiences of cancer patients and their families.”

Erin Bowles, MPH

Director, Collaborative Science, Kaiser Permanente Washington Health Research Institute

Twitter: @ErinJBowles


 

Biography

Epidemiologist Erin Bowles, MPH, is looking at breast cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.

Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Kaiser Permanente Breast Cancer Survivors Cohort — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of breast cancer screening and cancer treatment.

Her current work includes:

  • Collaborating on a multi-site study with investigators from Memorial Sloan Kettering Cancer Center, Kaiser Permanente Northern California, and Rutgers University to understand how obesity affects chemotherapy treatment dosing and risks of recurrence and toxicity in women with breast cancer
  • Helping investigators from Kaiser Permanente Northern California and the University of California (UC) San Francisco and UC Davis understand imaging trends in children and pregnant women, and subsequent risks of leukemia associated with ionizing radiation from imaging exams
  • Working with investigators from the NCI, Kaiser Permanente Colorado, Kaiser Permanente Georgia, and Kaiser Permanente Hawaii to study how mammographic breast density, radiation treatment, and tissue biomarkers are associated with second cancers in women with previous breast cancer
  • Collaborating on several studies within the BCSC to understand how disparities, access to advanced technology like artificial intelligence, and social drivers of health affect breast cancer screening, diagnosis, and surveillance
  • Working with teams from the Centers for Disease Control and Prevention, University of Washington, Henry Ford Health System, and Multicare Health System to develop and validate questions about cancer screening for people eligible for breast, colorectal, cervical, and/or lung cancer screening for the National Health Interview Survey.

Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20+ years has provided her with expertise in data collection and quality control for many subject areas. She is also Director of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to collaborative scientists with a range of skills and expertise. She is passionate about providing long-term career paths for masters- and PhD-level scientists who don’t want to become independent investigators.

Research interests and experience

  • Cancer

    Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data

  • Health Services & Economics

    Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation

  • Women's Health

    Menopause; hormone replacement therapy (HRT); breast cancer

  • Aging & Geriatrics

    Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer

Recent publications

Aiello Bowles EJ, Ramin C, Vo JB, Feigelson HS, Gander JC, Veiga LHS, Bodelon C, Curtis RE, Brandt C, Berrington de Gonzalez A, Gierach GL. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001-2018. Breast Cancer Res Treat. 2024 Aug 16. doi: 10.1007/s10549-024-07453-0. Online ahead of print. PubMed

Bhimani J, O’Connell K, Persaud S, Blinder V, Burganowski R, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, Bowles EJA, Kushi LH, Kantor ED. Patient characteristics associated with intended non-guideline chemotherapy in women with stage I-IIIA breast cancer. Cancer Epidemiol Biomarkers Prev. 2024 Jul 25. doi: 10.1158/1055-9965.EPI-24-0360. Online ahead of print. PubMed

Bhimani J, O’Connell K, Persaud S, Blinder V, Burganowski R, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Rivera DR, Roh JM, Tabatabai S, Valice E, Bandera EV, Bowles EJA, Kushi LH, Kantor ED. Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer. Int J Cancer. 2024 Jul 6. doi: 10.1002/ijc.35053. Online ahead of print. PubMed

Bhimani J, O'Connell K, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Bowles EJA, Bandera EV, Kushi LH, Kantor ED. Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019.  Breast Cancer Res. 2024;26(1):101. doi: 10.1186/s13058-024-01822-9.  PubMed

Vo JB, Ramin C, Veiga LHS, Brandt C, Curtis RE, Bodelon C, Barac A, Roger VL, Feigelson HS, Buist DSM, Bowles EJA, Gierach GL, Berrington de González A. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in U.S. breast cancer survivors. J Natl Cancer Inst. 2024 May 8:djae107. doi: 10.1093/jnci/djae107. [Epub ahead of print]. PubMed

Bhimani J, O'Connell K, Ergas IJ, Foley M, Gallagher GB, Griggs JJ, Heon N, Kolevska T, Kotsurovskyy Y, Kroenke CH, Laurent CA, Liu R, Nakata KG, Persaud S, Rivera DR, Roh JM, Tabatabai S, Valice E, Bowles EJA, Bandera EV, Kushi LH, Kantor ED. Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer.  JCO Clin Cancer Inform. 2024;8:e2300209. doi: 10.1200/CCI.23.00209.  PubMed

 

News

Breast_Cancer_Risk_Prediction_Model_1col.jpg

Predicting breast cancer risk after a high-risk benign lesion diagnosis

New study will develop risk models to improve clinical guidelines and practice.

Breast Cancer Surveillance

Kaiser Permanente Washington Breast Cancer Surveillance Registry

Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.

Healthy Findings Blog

KPWHRI-Collaborative-Science-Division-team-meeting_1col.jpg

Meet KPWHRI’s collaborative scientists

The division contributes to research across the institute with methodological and subject matter expertise.

KPWHRI in the media

Reduced-dose chemotherapy more common in older women

Erin Bowles on age at breast cancer diagnosis and chemotherapy dose in older women

MedPage Today, March 4, 2025

Research

Cancer-prevention-story_1col.jpg

Improving cancer prevention and early detection

How KPWHRI is contributing to better cancer screening and better outcomes for patients.